# Akshay S. Desai

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/akshay-s-desai/

## Facts

| Field | Value |
| --- | --- |
| Citations | 58,055 |
| Field | Heart Failure Treatment and Management |
| h-index | 102 |
| i10-index | 350 |
| Last Known Institution | Brigham and Women's Hospital |
| OpenAlex ID | https://openalex.org/A5101703850 |
| ORCID iD | 0000-0002-1443-0701 |
| Works | 652 |

## Researcher papers

Showing 12 of 24.

- [Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-patients-with-heart-failure-and-reduced-ejection-fraction/)
- [Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-versus-enalapril-in-heart-failure/)
- [Spironolactone for Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/spironolactone-for-heart-failure-with-preserved-ejection-fraction/)
- [Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-heart-failure-with-mildly-reduced-or-preserved-ejection/)
- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes](https://scholariq.org/papers/cardiorenal-end-points-in-a-trial-of-aliskiren-for-type-2-diabetes/)
- [Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial](https://scholariq.org/papers/regional-variation-in-patients-and-outcomes-in-the-treatment-of-preserved/)
- [SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials](https://scholariq.org/papers/sglt2-inhibitors-in-patients-with-heart-failure-a-comprehensive-meta-analysis-of/)
- [2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials](https://scholariq.org/papers/2017-cardiovascular-and-stroke-endpoint-definitions-for-clinical-trials/)
- [Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure](https://scholariq.org/papers/angiotensin-receptor-neprilysin-inhibition-compared-with-enalapril-on-the-risk/)
- [Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update](https://scholariq.org/papers/type-2-diabetes-mellitus-and-heart-failure-a-scientific-statement-from-the/)
- [Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure](https://scholariq.org/papers/treatment-of-anemia-with-darbepoetin-alfa-in-systolic-heart-failure/)

## Researcher topics

- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Cardiac pacing and defibrillation studies](https://scholariq.org/topics/cardiac-pacing-and-defibrillation-studies/)
- [Hormonal Regulation and Hypertension](https://scholariq.org/topics/hormonal-regulation-and-hypertension/)

## Researcher university

- [Brigham and Women's Hospital](https://scholariq.org/institutions/brigham-and-women-s-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.